Free Trial

Goldman Sachs Group Inc. Boosts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories logo with Medical background

Goldman Sachs Group Inc. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 454.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 144,333 shares of the medical research company's stock after purchasing an additional 118,304 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.51% of Bio-Rad Laboratories worth $46,604,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BIO. Treasurer of the State of North Carolina raised its stake in shares of Bio-Rad Laboratories by 0.4% in the third quarter. Treasurer of the State of North Carolina now owns 9,491 shares of the medical research company's stock valued at $3,402,000 after acquiring an additional 40 shares during the period. Parallel Advisors LLC grew its stake in shares of Bio-Rad Laboratories by 36.8% during the fourth quarter. Parallel Advisors LLC now owns 171 shares of the medical research company's stock worth $55,000 after acquiring an additional 46 shares during the last quarter. Signaturefd LLC increased its position in shares of Bio-Rad Laboratories by 15.8% in the 4th quarter. Signaturefd LLC now owns 352 shares of the medical research company's stock valued at $114,000 after acquiring an additional 48 shares during the period. Gladius Capital Management LP increased its holdings in Bio-Rad Laboratories by 65.8% in the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company's stock worth $39,000 after buying an additional 48 shares during the period. Finally, Yousif Capital Management LLC raised its holdings in shares of Bio-Rad Laboratories by 1.9% during the fourth quarter. Yousif Capital Management LLC now owns 2,775 shares of the medical research company's stock worth $896,000 after purchasing an additional 51 shares during the last quarter. Institutional investors own 65.24% of the company's stock.


Bio-Rad Laboratories Trading Up 0.8 %

Bio-Rad Laboratories stock traded up $2.17 during trading on Friday, hitting $287.79. The company had a trading volume of 1,318,032 shares, compared to its average volume of 221,663. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $431.79. The company's 50 day simple moving average is $285.18 and its 200-day simple moving average is $311.43. The stock has a market cap of $8.21 billion, a price-to-earnings ratio of -27.78 and a beta of 0.95. The company has a current ratio of 6.57, a quick ratio of 4.89 and a debt-to-equity ratio of 0.13.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.25. The firm had revenue of $610.82 million for the quarter, compared to the consensus estimate of $619.09 million. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The company's quarterly revenue was down 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 EPS. As a group, analysts expect that Bio-Rad Laboratories, Inc. will post 10.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BIO. Jefferies Financial Group reaffirmed a "hold" rating and set a $315.00 target price (down from $440.00) on shares of Bio-Rad Laboratories in a report on Monday, June 3rd. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Tuesday, May 28th. Citigroup cut Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their target price for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Finally, UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating for the company in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $436.67.

Read Our Latest Stock Report on Bio-Rad Laboratories

Insiders Place Their Bets

In other news, EVP Michael Crowley sold 369 shares of the business's stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $281.91, for a total transaction of $104,024.79. Following the completion of the transaction, the executive vice president now directly owns 6,573 shares of the company's stock, valued at $1,852,994.43. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 17.06% of the company's stock.

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Read More

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Should you invest $1,000 in Bio-Rad Laboratories right now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Top Market Leaders Splitting Their Stocks
How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines